Status | Study |
Active, not recruiting |
Study Name: Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2012-10-03 Interventions: Drug: Nilotinib |
Completed |
Study Name: Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2012-08-07 Interventions: Drug: Dasatinib tablets, oral, 100 mg, Once daily, Up to12 months on study, |
Withdrawn |
Study Name: Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms Condition: Leukemia, Myeloid, Chronic-Phase Date: 2012-07-24 |
Active, not recruiting |
Study Name: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2012-05-04 Interventions: Drug: Imatinib Other Names: |
Active, not recruiting |
Study Name: Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy Condition: Chronic Phase CML Date: 2011-10-14 Interventions: Behavioral: no access to eMedonline |
Completed |
Study Name: Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey Condition: Leukemia, Myeloid, Chronic-Phase (CML-CP) Date: 2010-08-24 Interventions: Drug: Imatinib Drug being observed but not provided |
Active, not recruiting |
Study Name: A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib Condition: Leukemia Date: 2008-10-21 Interventions: Drug: Dasatinib Other Name: Sprycel (BMS-354825) |
Terminated |
Study Name: Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib Condition: Leukemia, Myeloid, Chronic Date: 2006-05-01 Interventions: Drug: Imatinib Imatinib tablet |
Completed |
Study Name: PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML Condition: Chronic Myeloid Leukemia Date: 2006-03-15 Interventions: Drug: Peg Interferon Alpha 2b (Peg Intron) |
Active, not recruiting |
Study Name: Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) Condition: Leukemia, Myelogenous, Chronic Date: 2005-08-11 Interventions: Drug: Nilotinib 400 mg orally twice daily Other Name |